Wells Fargo & Company Kala Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.25 - $0.36 $21 - $30	84 Added 1.44%	5,900 $2,000
Q2 2022 Aug 12, 2022	SELL	$0.3 - $1.31 $2,218 - $9,686	-7,394 Reduced 55.97%	5,816 $2,000
Q1 2022 May 16, 2022	SELL	$0.61 - $1.84 $9,331 - $28,146	-15,297 Reduced 53.66%	13,210 $18,000
Q4 2021 Feb 14, 2022	BUY	$1.16 - $2.74 $31,908 - $75,369	27,507 Added 2750.7%	28,507 $34,000
Q2 2021 Aug 16, 2021	SELL	$5.06 - $8.15 $32,586 - $52,486	-6,440 Reduced 86.56%	1,000 $5,000

Q1 2021 May 13, 2021	SELL	$6.24 - $9.58 $428,787 - $658,299	-68,716 Reduced 90.23%	7,440 $50,000
Q4 2020 Feb 09, 2021	SELL	$6.28 - $8.79 $40,568 - $56,783	-6,460 Reduced 7.82%	76,156 $516,000
Q3 2020 Nov 05, 2020	SELL	$7.5 - $11.11 $184,170 - $272,817	-24,556 Reduced 22.91%	82,616 $620,000
Q2 2020 Aug 13, 2020	BUY	$8.33 - $13.79 $740,470 - $1.23 Million	88,892 Added 486.28%	107,172 $1.13 Million
Q1 2020 May 14, 2020	BUY	$3.83 - $8.79 $70,012 - $160,681	18,280 New	18,280 $161,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $10.4M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.